Zhangzhou Pientzehuang Pharmaceutical Co Ltd (600436)
Shanghai Stock Exchange · China · prices in CNY · close of 22 Oct 2026
Key indicators
| Last close | CNY 121.51 |
|---|---|
| 52-week range | 105.98 – 185.19 |
| Return, 1 month / 3 months | +0.6% / −13.2% |
| Return, 1 year / 3 years | −33.0% / −49.2% |
| Trend | Below its 200-day average |
| RSI (14) | 51 |
| Volatility (1 year) | 29.4% |
| Worst drawdown (1 year) | -45.3% |
| Average daily value traded | 507.43M CNY |
| Dividend yield | – |
Market X-Ray price-based
Five-year price chart navy: price · brown: 200-day average
About the company
Zhangzhou Pientzehuang Pharmaceutical makes traditional Chinese medicines, including its signature herbal formula Pientzehuang, which is used for treating inflammation and pain and is made with musk and other ingredients. The company also produces other traditional remedies and health products. It is based in Zhangzhou, in Fujian province, China, and its customers are mainly patients and consumers of traditional Chinese medicine in China and in overseas Chinese communities.
The shares are listed on the Shanghai Stock Exchange in China under the code 600436, and the price on this page is in Chinese yuan (CNY). Our dividend records, which start in 2019, show payments in 5 different calendar years. The Market X-Ray on this page is price-based and compares it with other stocks on the same exchange; it does not measure how healthy the business is.
Summary
Zhangzhou Pientzehuang Pharmaceutical Co Ltd (600436) trades on the Shanghai Stock Exchange in China. It last closed at CNY 121.51 on 22 October 2026.
Its price-based Market X-Ray is 54 out of 100 (a fair price profile), ranking 928 of 2,278 stocks on this exchange. The score describes how the stock has traded: trend, momentum, risk, liquidity and dividends, each ranked against the other stocks on its own exchange. It does not measure how healthy or cheap the business is.
Over the last year the price fell 33.0% and over the last three months it fell 13.2%. Returns are price returns, dividends not included.
Fundamental measures (valuation, growth, financial health) are not shown: we do not yet hold financial statements for this market.
The five lenses in numbers each metric is ranked against the other stocks on Shanghai Stock Exchange
| Lens and metric | Value | Score | Reading |
|---|---|---|---|
| Trend | 52 · Fair | Mixed trend against its averages. | |
| Above 200-day average | -12.9% | ||
| From 52-week high | -33.3% | ||
| Momentum | 30 · Weak | Lagging most stocks on this exchange. | |
| 3-month return | -13.2% | ||
| 6-month return | -14.4% | ||
| 12-month return, skipping the last month | -33.4% | ||
| Stability (higher is calmer) | 65 · Fair | Typical risk for this exchange. | |
| Volatility, 1 year (lower is calmer) | 29.4% | ||
| Worst drawdown, 1 year (smaller is calmer) | -45.3% | ||
| Liquidity | 82 · Strong | Trades actively. | |
| Average daily value traded | 507.43M CNY | ||
| Zero-volume days | 0.0% | ||
| Income | – | Pays no dividend. | |
| Dividend yield | – | ||
| Years with dividends | 2 |
Strengths
- Liquidity: Trades actively.
Weak spots
- Momentum: Lagging most stocks on this exchange.
Returns
| 1 week | +1.4% |
|---|---|
| 1 month | +0.6% |
| 3 months | −13.2% |
| 6 months | −14.4% |
| 1 year | −33.0% |
| 3 years | −49.2% |
| 5 years | −71.8% |
Signals
| 50-day / 200-day average | 123.87 / 139.54 |
|---|---|
| Golden / death cross (60 days) | None |
| New 52-week high | No |
| Bullish RSI divergence | No |
| Average daily range (ATR) | 3.14 |
Technical summary
Recent dividends
| Ex-dividend date | Amount per share |
|---|---|
| 12 Jul 2023 | CNY 1.2500 |
| 15 Jul 2022 | CNY 1.2100 |
| 25 Jun 2021 | CNY 0.9000 |
| 24 Jun 2020 | CNY 0.8200 |
| 27 Jun 2019 | CNY 0.6000 |
How to read this report
Every number comes from end-of-day prices and dividends. The Market X-Ray describes how the stock has traded, ranked against the other stocks on Shanghai Stock Exchange; it does not measure how healthy or cheap the business is. The fundamental X-Ray (financial health, valuation, growth) needs financial statements, which we hold today for US stocks. See the methodology page. Educational only, not financial advice.